glp-1 news today 2025 health pharma obesity drugs october Outlook for obesity in 2025: more health pharma news today obesity
Description
prices closer to global standards.
The focus is on making sure yo
The review urges nurse practitioners to balance expanding clinical promise with careful prescribing, patient education, monitoring, access advocacy, and vigilance for gastrointestinal, endocrine, pregnancy-related, and rare serious risks.
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic drugs that improve glycemic control and many other atherosclerosis-related parameters in patients with type 2 diabetes (T2D)
Random-effects models were applied, and sensitivity analyses examined result stability
Novo Nordisk is putting down up to US$362m to tap into Ascendis TransCon technology for treatments in metabolic and cardiovascular diseases
